切换至 "中华医学电子期刊资源库"
高级检索
中华消化病与影像杂志(电子版)

中华消化病与影像杂志(电子版) ›› 2018, Vol. 08 ›› Issue (01) : 24 -28. doi: 10.3877/cma.j.issn.2095-2015.2018.01.006

所属专题： 文献；

循证医学

替诺福韦酯与恩替卡韦在治疗慢性乙型肝炎的安全性与有效性的荟萃分析
尹丹萍1, 陈春明2,†()   
  1. 1. 250031　济南军区总医院疾病预防控制科
    2. 250031　济南军区总医院医务部
  • 收稿日期:2017-12-06 出版日期:2018-02-01
  • 通信作者: 陈春明
  • 基金资助:
    2015年度济南军区总医院院长基金(2015QN02)

Safety and efficacy comparison between tenofovir and entecavir in treatment of chronic hepatitis B: a Meta-analysis

Danping Yin1, Chunming Chen2,†()   

  1. 1. Department of Disease Prevention and Contrl, General Hospital of Jinan Military Command, Jinan 250031, China
    2. Department of Medical Administration, General Hospital of Jinan Military Command, Jinan 250031, China
  • Received:2017-12-06 Published:2018-02-01
  • Corresponding author: Chunming Chen
  • About author:
    Corresponding author: Chen Chunming, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

尹丹萍, 陈春明. 替诺福韦酯与恩替卡韦在治疗慢性乙型肝炎的安全性与有效性的荟萃分析[J/OL]. 中华消化病与影像杂志(电子版), 2018, 08(01): 24-28.

Danping Yin, Chunming Chen. Safety and efficacy comparison between tenofovir and entecavir in treatment of chronic hepatitis B: a Meta-analysis[J/OL]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2018, 08(01): 24-28.

目的

评估与比较恩替卡韦与替诺福韦酯在治疗慢性慢性乙型肝炎有效性及安全性。

方法

检索Pubmed/Medicine、Embase、Cochrane library数据库，恩替卡韦与替诺福韦酯治疗慢性乙型肝炎的研究，检索时间从数据库建立至2017年11月，由2名作者对检索数据进行提取与总结，运用Stata 12.0对数据进行统计学分析。

结果

共纳入此次荟萃分析共13篇，替诺福韦酯与恩替卡韦治疗HBV-DNA有效性方面，按照口服抗病毒药物时间，可分为2个亚组，24、48周其相对危险度与可信区间分别为：RR＝1.00，95% CI(0.90～1.11)，I2＝30%，P＝0.152；RR＝1.08，95% CI(1.00～1.16)，I2＝53%，P＝0.016。

结论

随访时间为24和48周时，在治疗慢性乙型肝炎HBV-DNA转阴率方面二者疗效相当。

关键词: 替诺福韦酯, 恩替卡韦, 慢性乙型肝炎, Meta分析
Objective

To evaluate and compare the efficacy and safety of entecavir and tenofovir in treatment of chronic hepatitis B.

Methods

The researches on entecavir and tenofovir in treatment of chronic hepatitis B were searched in PubMed/Medicine, EMBase, Cochrane Library databases until November 2017.Two authors independently extracted and summarized the data.Stata 12.0 software was used to analyze the data.

Results

A total of 13 studies were included in this Meta-analysis.In the aspect of therapeutic effectiveness of tenofovir and entecavir for HBV-DNA, the research objects were divided into two subgroups according to the use time of oral antiviral drug, and the relative risk(RR)and confidence interval(CI)of 24 weeks and 48 weeks subgroup were as follows: RR=1.00, 95% CI(0.90-1.11), I2=30%, P=0.152; RR=1.08, 95% CI(1.00-1.16), I2=53%, P=0.016.

Conclusion

Tenofovir has a similar efficacy in HBV-DNA negative conversion ratio compared with entecavir in follow-up time 24 and 48 weeks.

Key words: Tenofovir, Entecavir, Chronic hepatitis B, Meta-analysis
图1 随访时间为24周二者在治疗HBV-DNA有效性方面对比
图2 随访时间为48周二者在治疗HBV-DNA有效性方面对比
图3 随访时间为48周二者在治疗HBV-DNA有效性方面敏感性分析
图4 随访时间为48周二者在治疗HBV-DNA有效性方面Begg′s检验
1
World Health Organization.Guidelines for the prevention, care and treatment of persons with chronic Hepatitis B infection[R]. Geneva: WHO, 2015.
2
European Association for the Study of the Liver.EASL 2017 Clinical practice guildelines on the management of Hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
3
Park JW, Kwak KM, Kim SE, et al.Comparison of the long-term efficacy between entecavir and tenofovir in treatment-naïve chronic hepatitis B patients[J]. BMC Gastroenterol, 2017, 17: 39.
4
Wu IT, Hu TH, Hung CH, et al.Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naïve chronic hepatitis B patients with high viremia: a retrospective cohort study[J]. Clin Microbiol Infect, 2017, 23(7): 464-469.
5
Pereira CV, Tovo CV, Grossmann TK, et al.Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil[J]. Mem Inst Oswaldo Cruz, 2016, 111(4): 252-257.
6
Centeno BL, Borrell RC, Encinas MP, et al.Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B[J]. Farm Hosp, 2016, 40(4): 279-286.
7
Shi H, Huang M, Lin G, et al.Efficacy comparison of tenofovir and entecavir in HBeAg-positive chronic hepatitis B patients with high HBV DNA[J]. Biomed Res Int, 2016, 2016: 6725073.
8
Yu HM, Kwon SY, Kim J, et al.Virologic response and safety of tenofovir versus entecavir in treatment-naive chronic Hepatitis B patients[J]. Saudi J Gastroenterol, 2015, 21(3): 146-151.
9
Gao L, Trinh HN, Li J, et al.Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA Nguyen[J]. Aliment Pharmacol Ther, 2014, 39(6): 629-637.
10
Ha NB, Trinh HN, Rosenblatt L, et al.Treatment outcomes with first-line therapies with entecavir and tenofovir in treatment-naive chronic hepatitis B patients in a routine clinical practice[J]. J Clin Gastroenterol, 2016, 50(2): 169-174.
11
Güzelbulut F, Ovünç AO, Oetinkaya ZA, et al.Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B[J]. Hepatogastroenterology, 2012, 59(114): 477-480.
12
Ozaras R, Mete B, Ceylan B, et al.First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment[J]. Eur J Gastroenterol Hepatol, 2014, 26(7): 774-780.
13
Kwon YJ, Lee HS, Park MJ, et al.Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B[J]. Niger J Clin Pract, 2015, 18(6): 796-801.
14
Jayakumar R1, Joshi YK, Singh S. Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir[J]. J Lab Physicians, 2012, 4(1): 10-16.
15
Dogan Z, Filik L, Ergül B, et al.Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis[J]. Saudi J Gastroenterol, 2015, 21(6): 396-399.
16
Yegin EG, Ozdogan OC.Partial virological response to three different nucleotide analogues in na？ve patients with chronic hepatitis B [J]. Hepatobiliary Pancreat Dis Int, 2014, 13(6): 602-611.
17
安纪红．恩替卡韦分散片治疗HBeAg阳性慢性乙型肝炎患者48周临床分析[J]．中华传染病杂志，2012，30(11): 699-701.
18
Liaw YF, Sheen IS, Lee CM, et al.Tenofovir disoproxil fumarate(TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease [J]. Hepatology, 2011, 53(1): 62-72.
19
Sriprayoon T, Lueangarum S, Suwanwela C, et al.Efficacy and safety of Entecavir versus Tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial [J]. Gastroenterology, 2012, 142: S695.
20
Tien C, Xu JJ, Chan LS, et al.Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling [J]. Dig Dis Sci, 2015, 60(2): 566-572.
21
Miquel M, Núñez O, Trapero-Marugán M, et al.Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice [J]. Ann Hepatol, 2013, 12(2): 205-212.
[1] 蚁淳, 袁冬生, 熊学军. 系统免疫炎症指数与骨密度降低和骨质疏松的关联[J/OL]. 中华关节外科杂志(电子版), 2024, 18(05): 609-617.
[2] 李志文, 李远志, 李华, 方志远. 糖皮质激素治疗膝骨关节炎疗效的网状Meta分析[J/OL]. 中华关节外科杂志(电子版), 2024, 18(04): 484-496.
[3] 吴姗姗, 潘裕民, 刘晋, 张劲松, 乔莉. 睡眠呼吸暂停综合征患者静脉血栓栓塞症发生率的Meta分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 312-317.
[4] 程鹏, 杨道鸿, 邓文君, 钟宇琼, 胡晓雪, 黄小银, 周道扬. 纤维蛋白原治疗创伤性凝血病有效性和安全性的Meta分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(03): 225-231.
[5] 沈皓, 张驰, 韩旻轩, 陆晓庆, 周愉, 周莉丽. 骨皮质切开术对正畸治疗牙根吸收影响的Meta分析[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(03): 175-184.
[6] 郭仁凯, 武慧铭, 李辉宇. 机器人辅助全系膜切除术治疗右半结肠癌有效性和安全性的Meta分析及试验序贯分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(03): 234-240.
[7] 朱俊佳, 孙琦, 徐文龙, 陆天宇, 冯强, 储涛, 邢春根, 高春冬, 俞一峰, 赵振国. 永久性结肠造口预防性补片置入对预防造口旁疝价值的Meta分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(03): 336-342.
[8] 王招荐, 曹桢, 郭小双, 靳小雷, 刘子文. 加速康复外科理念应用于腹壁重建手术的系统评价及Meta分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(03): 343-350.
[9] 马振威, 宋润夫, 王兵. ERCP胆道内支架与骑跨十二指肠乳头支架置入治疗不可切除肝门部胆管癌疗效的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 807-812.
[10] 龚财芳, 赵俊宇, 游川. 围手术期肠内营养在肝癌肝切除患者中有效性及安全性的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 551-556.
[11] 郁凯, 曾保起, 杨剑, 杨杰, 张殿英, 孙凤. 全关节镜与切开手术治疗肩袖撕裂疗效比较的系统综述与Meta分析[J/OL]. 中华肩肘外科电子杂志, 2024, 12(03): 238-245.
[12] 史敬萱, 焦圆圆, 田景玮, 卓莉. 间充质干细胞来源外泌体治疗动物糖尿病肾脏病的效果：Meta分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(02): 79-86.
[13] 王芳, 刘达, 左智炜, 盛金平, 陈庭进, 蒋锐. 定量CT与双能X线骨密度仪对骨质疏松诊断效能比较的Meta分析[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 363-371.
[14] 江浩, 余宏圣, 杨碧兰, 阿布都克尤木·斯马依, 吴斌, 杨逸冬. 基于列线图模型对慢性乙型肝炎合并肝脏脂肪变性患者并发晚期肝纤维化的临床预测[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 114-120.
[15] 周倩妹, 王宪娥, 徐筱, 老慧琳, 赵欣悦, 胡菁颖. 多元化系统护理对老年人群牙周健康指标影响的系统评价[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 500-506.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号